Precigen, Inc. PGEN

Updated: 16 Jun 2026

NASDAQ | Biotech | Gene and cell therapies

No signal published yet

We already track Precigen and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Precigen free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Gene and cell therapies
We're already tracking Precigen, Inc. — here are the latest events we've registered

Recent News

  • On June 15, 2026, Precigen announced that the FDA granted orphan drug exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis. This exclusivity provides market protection for the therapy through August 2032.

What Firelda Watch includes for Precigen, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Precigen, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Moderna, Inc.
MRNA
HOLD
AstraZeneca PLC
AZN
HOLD
Calliditas Therapeutics
CALT
NEUTRAL
Ionis Pharmaceuticals, Inc.
IONS
HOLD
Exelixis, Inc.
EXEL
HOLD

Biotech

More companies in this sector

Want to follow Precigen, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Precigen free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Precigen, Inc. PGEN
Precigen — follow and we'll monitor it
Follow Precigen free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.